Drug discovery for schizophrenia: from PNS to CNS and back
Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in pati...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Book |
| Language: | English |
| Published: |
Cambridge
Royal Society of Chemistry
[2024]
|
| Series: | Drug discovery series
No. 84 |
| Subjects: | |
| Summary: | Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in patients with schizophrenia. Although 75% of neural information passes through the PNS, interactions between the PNS and CNS in schizophrenia remain understudied. Consequently, the current view of schizophrenia requires improvement to facilitate diagnostics and drug development.In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication). Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential. Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models |
| Item Description: | - Genetic Architecture of Schizophrenia: Transitioning from Candidate Genes to Polygenic Risk Scores; - Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discovery; - Combinatorial Behavioural Phenotyping of Mouse Models of Schizophrenia; - Beyond Brain Boundaries: The Emerging Significance of Vagal Body-to-brain Communication in Schizophrenia; - Iron Dyshomeostasis in Schizophrenia and Potential Treatments to Mitigate Its Effects; - Smell of Dopamine in Schizophrenia: Towards Drug-discovery; - Aromatherapy: A Novel Approach to Schizophrenia Treatment; - Emerging Non-invasive Brain Stimulations for Schizophrenia; - From Circuits to Drug Targets: The Promise Of Opto- and Chemogenetics for Drug Discovery; - Therapeutic Implications of Recent Genomic Discoveries in Schizophrenia |
| Physical Description: | XV, 247 Seiten Illustrationen 537 gr |
| ISBN: | 9781837672059 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV050211161 | ||
| 003 | DE-604 | ||
| 005 | 20250430 | ||
| 007 | t| | ||
| 008 | 250319s2024 xx a||| |||| 00||| eng d | ||
| 020 | |a 9781837672059 |9 978-1-83767-205-9 | ||
| 024 | 3 | |a 9781837672059 | |
| 035 | |a (DE-599)BVBBV050211161 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29T | ||
| 245 | 1 | 0 | |a Drug discovery for schizophrenia |b from PNS to CNS and back |c edited by Tatiana V. Lipina, University of Toronto, Canada |
| 264 | 1 | |a Cambridge |b Royal Society of Chemistry |c [2024] | |
| 300 | |a XV, 247 Seiten |b Illustrationen |c 537 gr | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Drug discovery series |v No. 84 | |
| 500 | |a - Genetic Architecture of Schizophrenia: Transitioning from Candidate Genes to Polygenic Risk Scores; - Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discovery; - Combinatorial Behavioural Phenotyping of Mouse Models of Schizophrenia; - Beyond Brain Boundaries: The Emerging Significance of Vagal Body-to-brain Communication in Schizophrenia; - Iron Dyshomeostasis in Schizophrenia and Potential Treatments to Mitigate Its Effects; - Smell of Dopamine in Schizophrenia: Towards Drug-discovery; - Aromatherapy: A Novel Approach to Schizophrenia Treatment; - Emerging Non-invasive Brain Stimulations for Schizophrenia; - From Circuits to Drug Targets: The Promise Of Opto- and Chemogenetics for Drug Discovery; - Therapeutic Implications of Recent Genomic Discoveries in Schizophrenia | ||
| 520 | |a Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in patients with schizophrenia. Although 75% of neural information passes through the PNS, interactions between the PNS and CNS in schizophrenia remain understudied. Consequently, the current view of schizophrenia requires improvement to facilitate diagnostics and drug development.In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication). | ||
| 520 | |a Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential. | ||
| 520 | |a Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models | ||
| 650 | 4 | |a bicssc | |
| 650 | 4 | |a bicssc / Psychiatry | |
| 650 | 4 | |a bicssc / CHEMISTRY | |
| 650 | 4 | |a bisacsh | |
| 650 | 4 | |a bisacsh / MEDICAL / Pharmacology | |
| 650 | 4 | |a bisacsh / SCIENCE / Life Sciences / Biochemistry | |
| 700 | 1 | |a Lipina, Tatiana V. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |z 978-1-83767-746-7 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, EPUB |z 978-1-83767-693-4 |
| 830 | 0 | |a Drug discovery series |v No. 84 |w (DE-604)BV036776227 |9 84 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-035546330 | |
Record in the Search Index
| _version_ | 1830821309791076352 |
|---|---|
| adam_text | |
| any_adam_object | |
| author | Lipina, Tatiana V |
| author2 | Lipina, Tatiana V. |
| author2_role | edt |
| author2_variant | t v l tv tvl |
| author_facet | Lipina, Tatiana V Lipina, Tatiana V. |
| author_role | aut |
| author_sort | Lipina, Tatiana V |
| author_variant | t v l tv tvl |
| building | Verbundindex |
| bvnumber | BV050211161 |
| ctrlnum | (DE-599)BVBBV050211161 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV050211161</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20250430</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">250319s2024 xx a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781837672059</subfield><subfield code="9">978-1-83767-205-9</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9781837672059</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV050211161</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug discovery for schizophrenia</subfield><subfield code="b">from PNS to CNS and back</subfield><subfield code="c">edited by Tatiana V. Lipina, University of Toronto, Canada</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Royal Society of Chemistry</subfield><subfield code="c">[2024]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV, 247 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">537 gr</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Drug discovery series</subfield><subfield code="v">No. 84</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">- Genetic Architecture of Schizophrenia: Transitioning from Candidate Genes to Polygenic Risk Scores; - Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discovery; - Combinatorial Behavioural Phenotyping of Mouse Models of Schizophrenia; - Beyond Brain Boundaries: The Emerging Significance of Vagal Body-to-brain Communication in Schizophrenia; - Iron Dyshomeostasis in Schizophrenia and Potential Treatments to Mitigate Its Effects; - Smell of Dopamine in Schizophrenia: Towards Drug-discovery; - Aromatherapy: A Novel Approach to Schizophrenia Treatment; - Emerging Non-invasive Brain Stimulations for Schizophrenia; - From Circuits to Drug Targets: The Promise Of Opto- and Chemogenetics for Drug Discovery; - Therapeutic Implications of Recent Genomic Discoveries in Schizophrenia</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in patients with schizophrenia. Although 75% of neural information passes through the PNS, interactions between the PNS and CNS in schizophrenia remain understudied. Consequently, the current view of schizophrenia requires improvement to facilitate diagnostics and drug development.In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bicssc / Psychiatry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bicssc / CHEMISTRY</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bisacsh / MEDICAL / Pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bisacsh / SCIENCE / Life Sciences / Biochemistry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lipina, Tatiana V.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-1-83767-746-7</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-1-83767-693-4</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Drug discovery series</subfield><subfield code="v">No. 84</subfield><subfield code="w">(DE-604)BV036776227</subfield><subfield code="9">84</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-035546330</subfield></datafield></record></collection> |
| id | DE-604.BV050211161 |
| illustrated | Illustrated |
| indexdate | 2025-04-30T10:01:01Z |
| institution | BVB |
| isbn | 9781837672059 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-035546330 |
| open_access_boolean | |
| owner | DE-29T |
| owner_facet | DE-29T |
| physical | XV, 247 Seiten Illustrationen 537 gr |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| publisher | Royal Society of Chemistry |
| record_format | marc |
| series | Drug discovery series |
| series2 | Drug discovery series |
| spelling | Drug discovery for schizophrenia from PNS to CNS and back edited by Tatiana V. Lipina, University of Toronto, Canada Cambridge Royal Society of Chemistry [2024] XV, 247 Seiten Illustrationen 537 gr txt rdacontent n rdamedia nc rdacarrier Drug discovery series No. 84 - Genetic Architecture of Schizophrenia: Transitioning from Candidate Genes to Polygenic Risk Scores; - Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discovery; - Combinatorial Behavioural Phenotyping of Mouse Models of Schizophrenia; - Beyond Brain Boundaries: The Emerging Significance of Vagal Body-to-brain Communication in Schizophrenia; - Iron Dyshomeostasis in Schizophrenia and Potential Treatments to Mitigate Its Effects; - Smell of Dopamine in Schizophrenia: Towards Drug-discovery; - Aromatherapy: A Novel Approach to Schizophrenia Treatment; - Emerging Non-invasive Brain Stimulations for Schizophrenia; - From Circuits to Drug Targets: The Promise Of Opto- and Chemogenetics for Drug Discovery; - Therapeutic Implications of Recent Genomic Discoveries in Schizophrenia Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in patients with schizophrenia. Although 75% of neural information passes through the PNS, interactions between the PNS and CNS in schizophrenia remain understudied. Consequently, the current view of schizophrenia requires improvement to facilitate diagnostics and drug development.In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication). Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential. Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models bicssc bicssc / Psychiatry bicssc / CHEMISTRY bisacsh bisacsh / MEDICAL / Pharmacology bisacsh / SCIENCE / Life Sciences / Biochemistry Lipina, Tatiana V. edt Erscheint auch als Online-Ausgabe, PDF 978-1-83767-746-7 Erscheint auch als Online-Ausgabe, EPUB 978-1-83767-693-4 Drug discovery series No. 84 (DE-604)BV036776227 84 |
| spellingShingle | Lipina, Tatiana V Drug discovery for schizophrenia from PNS to CNS and back bicssc bicssc / Psychiatry bicssc / CHEMISTRY bisacsh bisacsh / MEDICAL / Pharmacology bisacsh / SCIENCE / Life Sciences / Biochemistry Drug discovery series |
| title | Drug discovery for schizophrenia from PNS to CNS and back |
| title_auth | Drug discovery for schizophrenia from PNS to CNS and back |
| title_exact_search | Drug discovery for schizophrenia from PNS to CNS and back |
| title_full | Drug discovery for schizophrenia from PNS to CNS and back edited by Tatiana V. Lipina, University of Toronto, Canada |
| title_fullStr | Drug discovery for schizophrenia from PNS to CNS and back edited by Tatiana V. Lipina, University of Toronto, Canada |
| title_full_unstemmed | Drug discovery for schizophrenia from PNS to CNS and back edited by Tatiana V. Lipina, University of Toronto, Canada |
| title_short | Drug discovery for schizophrenia |
| title_sort | drug discovery for schizophrenia from pns to cns and back |
| title_sub | from PNS to CNS and back |
| topic | bicssc bicssc / Psychiatry bicssc / CHEMISTRY bisacsh bisacsh / MEDICAL / Pharmacology bisacsh / SCIENCE / Life Sciences / Biochemistry |
| topic_facet | bicssc bicssc / Psychiatry bicssc / CHEMISTRY bisacsh bisacsh / MEDICAL / Pharmacology bisacsh / SCIENCE / Life Sciences / Biochemistry |
| volume_link | (DE-604)BV036776227 |
| work_keys_str_mv | AT lipinatatianav drugdiscoveryforschizophreniafrompnstocnsandback |